Overview

Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure

Status:
Terminated

Trial end date:
2003-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the safety of Pioglitazone, once daily (QD), to Glyburide in Type 2 Diabetes Subjects with Mild to Moderate Congestive Heart Failure

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Glyburide
Pioglitazone